Vimarsana
Biggest News Aggregation in the World

Page 3 - Benjamin Solomon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Benjamin Solomon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Benjamin Solomon Today - Breaking & Trending Today

Adjuvant Osimertinib Improves OS in EGFR-Mutant, Early-Stage NSCLC - Vimarsana News

Adjuvant Osimertinib Improves OS in EGFR-Mutant, Early-Stage NSCLC

Adjuvant osimertinib can improve OS in patients with EGFR-mutated, early-stage non-small-cell lung cancer, the ADAURA trial suggests.

Adjuvant Osimertinib Improves OS in EGFR-Mutant, Early-Stage NSCLC - Vimarsana News

Adjuvant Osimertinib Improves OS in EGFR-Mutant, Early-Stage NSCLC

Adjuvant osimertinib can improve OS in patients with EGFR-mutated, early-stage non-small-cell lung cancer, the ADAURA trial suggests.

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in P - Vimarsana News

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in P

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifiraf...

Lifirafenib/Mirdametinib Combination Is Safe and Tolerable in Advanced/Refractory Solid Tumors - Vimarsana News

Lifirafenib/Mirdametinib Combination Is Safe and Tolerable in Advanced/Refractory Solid Tumors

Lifirafenib plus mirdametinib produced a tolerable safety profile and antitumor activity in patients with BRAF- or KRAS-mutant advanced or refractory solid tumors.

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 - Vimarsana News

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in... | April 17, 2023